Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) this morning announced the creation of four new wholly-owned subsidiary companies: Lexaria CanPharm Corp., a Canadian company that provides DehydraTECH technology and other enhancements to the global cannabis industry; Lexaria Nicotine Corp., a US company with a global license to offer DehydraTECH technology to the global nicotine and tobacco industries; Lexaria Hemp Corp., a US company globally licensed to provide DehydraTECH to the burgeoning hemp-based foods and supplements industries; and Lexaria Pharmaceutical Corp., a US company internationally authorized to license DehydraTECH to the pharmaceutical sector, including pain relief, vitamins, hormone treatments, central nervous system conditions and more. To greater engage with the separate customer bases and business applications for each subsidiary, this new corporate structure enables Lexaria to focus its future research, potential financing structures and industry partnerships on options specifically suited for each new subsidiary. The company also plans to use wholly-owned Poviva Tea Corp. to advance the current ViPova Tea and Coffee consumer brands. In addition, Lexaria announced that it has received $33,000 from the exercise of 330,000 options at the price of $0.10 previously granted to a third party. The proceeds will be used for general corporate purposes.
To view the full press release, visit http://ibn.fm/mKqcZ
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. licenses disruptive patented delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECH™ delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com.
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.qualitystocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php
